New trial results published in medical journals suggest obesity weight loss can be maintained by shifting from higher-dose injectables to lower doses or switching to oral formulations. The updates focus on “maintenance” strategies—aiming to reduce rebound after initial weight loss rather than only driving further loss. Separately, an additional ECO2026 study found sustained weight loss improved with continued maximum-dose tirzepatide versus strategies that reduce therapy intensity. Together, the data are shaping payer and clinician conversations around how to structure long-term GLP-1 and incretin-based regimens. The direction of travel is clear: trials are increasingly designed around durability of response and adherence tradeoffs, including convenience of oral dosing versus ongoing injectable regimens. For biotech and pharma stakeholders, these findings strengthen the clinical evidence base supporting label-adjacent maintenance approaches and inform lifecycle strategy for obesity franchises.